


FORM PTO-1449		U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.	SERIAL NO.
				U013913-4	10/099858
 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use several sheets if necessary)</p>		APPLICANT			
		Bonnie M. Davis			
		FILING DATE		GROUP	
		March 14, 2002		1617	
U.S. PATENT DOCUMENTS					
EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER	DATE	NAME	FILING DATE IF APPROPRIATE
	AA				
	AB				
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				
FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
					YES      NO
	AL				
	AM				
	AN				
	AO				
	AP				
OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)					
	AR	Business Week January 28, 2008: article "Do Cholesterol Drugs do Any Good"			
	AS	Australian Adverse Drug Reactions Bulletin Vol 17 August 1998			
	AT	Wolzin et al "Decreased Prevalence of Alzheimer Disease with 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors			
EXAMINER			DATE CONSIDERED		
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

<b>FORM PTO-1449     U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>ATTY. DOCKET NO.</b>		<b>SERIAL NO.</b>		
		<b>U013913-4</b>		<b>10/099858</b>		
		<b>APPLICANT</b>				
		<b>Bonnie M. Davis</b>				
		<b>FILING DATE</b>		<b>GROUP</b>		
<b>March 14, 2003</b>		<b>1617</b>				
<b>U.S. PATENT DOCUMENTS</b>						
<b>EXAMINER INITIALS</b>	<b>REFERENCE DESIGNATION</b>	<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>NAME</b>	<b>FILING DATE IF APPROPRIATE</b>	
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
<b>FOREIGN PATENT DOCUMENTS</b>						
		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>COUNTRY</b>	<b>TRANSLATION</b>	
					<b>YES</b>	<b>NO</b>
	AL					
	AM					
	AN					
	AO					
	AP					
<b>OTHER ART    (Including Author, Title, Date, Pertinent Dates, Etc.)</b>						
	AU	Haley and Dietschy Editorial in Arch. Neurology Vol 57, Oct 2000 page 1409				
	AV	R. C. Petersen et al "Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence -based review)" Neurology 2001:56; 1122-1142				
	AW	Letters in Arch Neurol June 2001 : 1023 including letters by Lesser and Liebow Bollen, Gaw and Buckley				
<b>EXAMINER</b>			<b>DATE CONSIDERED</b>			
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

<b>FORM PTO-1449     U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>ATTY. DOCKET NO.</b>		<b>SERIAL NO.</b>		
		U-013913-4		10/099,858		
		<b>APPLICANT</b>				
		<b>Bonnie M Davis</b>				
		<b>FILING DATE</b>		<b>GROUP</b>		
March 14, 2003		1617				
<b>U.S. PATENT DOCUMENTS</b>						
<b>EXAMINER INITIALS</b>	<b>REFERENCE DESIGNATION</b>	<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>NAME</b>	<b>FILING DATE IF APPROPRIATE</b>	
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
<b>FOREIGN PATENT DOCUMENTS</b>						
		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>COUNTRY</b>	<b>TRANSLATION</b>	
					YES	NO
	AL					
	AM					
	AN					
	AO					
	AP					
<b>OTHER ART    (Including Author, Title, Date, Pertinent Dates, Etc.)</b>						
	AAA	Rockwood et al "Use of Lipid-Lowering Agents, Indication Bias, and the Risk of Dementia in Community-Dwelling Elderly People" Arch Neurol:59: Feb 2002				
	AAB	Yaffe et al "Serum lipoprotein Levels, Statin Use and Cognitive Function in Older Women" Arch Neurol 59 March 2002 p 378 et seq				
	AAC	Winblad et al "Effects of Statins on Cognitive Functions in Patients with Alzheimer's Disease in Galantamine Clinical Trials Drugs Aging 200724(1) 57 - 61				
<b>EXAMINER</b>			<b>DATE CONSIDERED</b>			
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

FORM PTO-1449		U. S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.	SERIAL NO.
				<u>U 013913-4</u>	<u>10/099858</u>
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		APPLICANT			
		<u>BOWNIE M. DAVIS</u>			
		FILING DATE		GROUP	
				<u>MARCH 14, 2002</u>	<u>167</u>

U.S. PATENT DOCUMENTS					
EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER	DATE	NAME	FILING DATE IF APPROPRIATE
	AA				
	AB				
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AL					
	AM					
	AN					
	AO					
	AP					

OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)		
	AX	Letters in Arch Neurol July 2001 58: 1160 by Golomb
	AY	Letters in Th Lancet March 17, 2002 by Bickenhager et al, by Cheung et al and by Blauw et al.
	AZ	MacMahon et al "Reliable Assessment of the effects of treatment on mortality and major mortality II: observational studied The Lancet 357:455 et seq.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	